[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"KLAVA Innovation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100648605","evaluation-of-the-efficacy-of-quitoxil-in-smoking-cessation-100648605",false,"NCT07722832","Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation","Evaluation of the Impact of the QUITOXIL® System on Smoking Cessation in Patients With Tobacco Use Disorder : a Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* Men or women aged between 18 and 65\n* Who have understood and signed the informed consent form\n* With a tobacco use disorder according to the diagnostic criteria of the DSM-5 and ICD-10.\n* Daily smoker of manufactured or hand-roll , consuming at least 5 cigarettes per day for ≥ 12 months.\n* Expressing a desire to stop smoking\n* Having undergone a motivational interview, having completed, or completing during the inclusion visit, a Richmond Test with a score \\> 5 as part of the smoking cessation process.\n* Starting, at the inclusion visit or at , first-line nicotine replacement therapy (NRT), with a duration of use not exceeding one month prior to inclusion.\n* Available to attend the scheduled visits and assessments, including setting aside 10 to 30 minutes per week throughout the study.\n* Owns a compatible smartphone (iOS ≥ 13.4 or Android ≥ 6.0) and has a valid email address.\n* Understand and be proficient in the French language, and be able to understand the study instructions.\n* Enrolled in or covered by a social security scheme, in accordance with local requirements\n\nExclusion Criteria:\n\n* Individuals who, at the time of inclusion ( ), have been receiving another form of non-pharmacological support for smoking cessation for more than one month (e.g. cognitive-behavioural therapy, psychotherapy, therapeutic education programmes, hypnosis, acupuncture, support groups, digital apps or tools to aid cessation, helplines, or any other behavioural or non-pharmacological intervention).\n* Anyone deemed by the investigator to lack autonomy.\n* Difficulties using a smartphone\n* Presenting with severe, unstabilised psychiatric disorders (defined as a patient admitted to a psychiatric ward), in particular: acute or transient psychotic disorders, bipolar disorder type I or II, other unstabilised bipolar or related disorders.\n* Participating in another interventional research trial (with the exception of the IMPULSION programme - Implementation of lung cancer screening in the population)\n* A person subject to a compulsory treatment order under a court order.\n* A person under guardianship, curatorship, judicial protection, or any other administrative or judicial measure resulting in a partial or total deprivation of rights and freedoms.","ALL","18 Years","65 Years",{"count":20,"type":21},606,"ESTIMATED","INTERVENTIONAL",[24],"NA","As part of post-marketing clinical monitoring and with a view to applying for the digital medical device Quitoxil® to be included on the LPPR list, this prospective, multicentre, controlled, randomised clinical trial aims to evaluate the clinical impact of support provided by Quitoxil® as an adjunct to conventional management for patients undergoing smoking cessation who have a tobacco use disorder.",[27],"Tobacco Use Disorder","NOT_YET_RECRUITING","2026-07-23",{"date":31,"type":32},"2026-07-24","ACTUAL",{"date":34,"type":21},"2026-10-01",{"date":36,"type":21},"2028-04-01",{"name":38,"class":39},"KLAVA Innovation","INDUSTRY",""]